Infectious Canine Hepatitis in Dogs: Symptoms, Diagnosis, Treatment, and Blue Eye Guide
Reviewed by a Licensed Veterinary Doctor (DVM)
Internal Medicine and Infectious Disease
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Infectious canine hepatitis (ICH) is caused by Canine Adenovirus type 1 (CAV-1), a non-enveloped double-stranded DNA virus in the family Adenoviridae; the non-enveloped structure makes it unusually resistant in the environment: CAV-1 survives for months on contaminated surfaces at room temperature, is resistant to quaternary ammonium compounds (a commonly used kennel disinfectant), and is killed only by sodium hypochlorite bleach (1:30 dilution), iodine-based disinfectants, and formaldehyde; this environmental persistence means that kennels, shelters, and yards contaminated by an infected or recently recovered dog remain infectious for prolonged periods and require thorough disinfection with the correct disinfectant to eliminate the virus.
- CAV-1 has a unique and clinically important tropism for two cell types: hepatocytes (causing the hepatic necrosis that defines the disease) and vascular endothelial cells throughout the body; the endothelial tropism is the pathological driver of the most severe clinical consequences; widespread endothelial cell infection and necrosis disrupts the coagulation cascade and triggers disseminated intravascular coagulation (DIC), causing the hemorrhagic signs that characterize severe ICH: petechiae, ecchymoses, prolonged bleeding from venipuncture sites, hematuria, and melena; the hallmark histopathological finding in both hepatocytes and endothelial cells is the Cowdry type A intranuclear inclusion body: an eosinophilic (pink) inclusion within the nucleus surrounded by a clear halo, representing viral replication complexes assembled within the nucleus; these inclusion bodies in hepatocytes, Kupffer cells, and endothelial cells on liver or tissue biopsy confirm the diagnosis.
- ICH presents in three clinical forms whose severity differs dramatically: the peracute form kills young unvaccinated dogs within hours to 24 hours before meaningful clinical signs develop (owners describe finding an apparently healthy dog dead); the acute form produces fever up to 41.5 degrees Celsius, profound lethargy, anorexia, vomiting, cranial abdominal pain on palpation (over the liver), tonsillitis, cervical lymphadenopathy, and signs of coagulopathy including petechiae and prolonged bleeding; the mild or subclinical form (the most common) causes only transient fever and lethargy before spontaneous recovery; at necropsy, the grossly thickened, edematous gallbladder wall is considered pathognomonic for ICH; the gallbladder wall edema, caused by plasma leakage through damaged endothelial cells into the gallbladder submucosa, is a distinctive finding that can also be detected by abdominal ultrasound in living dogs.
- The “blue eye” of ICH (also called hepatitis blue eye) is corneal edema producing a blue-grey opacity of the cornea that appears in approximately 20 to 25 percent of affected dogs during the convalescent phase, typically 7 to 10 days after the acute illness; the mechanism is immune complex (antigen-antibody) deposition in the corneal endothelium and anterior uvea, which triggers an inflammatory response causing endothelial dysfunction and corneal stromal edema; crucially, the blue eye appears during recovery, not at the height of illness, and is a sign of the immune response rather than active viral replication; in most dogs it resolves within 3 to 6 weeks without specific treatment, though a small percentage develop permanent corneal changes or secondary glaucoma; an identical “vaccine-associated blue eye” can occur in dogs receiving live CAV-1 vaccines, which is why all modern DHPP vaccines contain CAV-2 (Canine Adenovirus type 2) instead of CAV-1: CAV-2 provides complete cross-protective immunity against CAV-1 without causing uveitis.
- The most important and underappreciated fact about ICH from a public health and kennel management perspective is that dogs recovering from ICH shed CAV-1 in their urine for up to 6 to 9 months after clinical recovery; a dog that appears completely healthy and recovered continues to contaminate the environment and infect unvaccinated dogs through contact with its urine for the better part of a year after infection; this prolonged urinary shedding makes isolation of recovered dogs from unvaccinated contacts an ongoing management issue, not just an acute-phase concern; shelter operators, breeders, and owners of unvaccinated dogs need to understand that a “recovered” dog from a known ICH exposure is an infectious risk for months, not days.
- Treatment of ICH is supportive because no antiviral drug is specifically approved or proven effective against CAV-1 in dogs; the treatment priorities are: intravenous crystalloid fluid resuscitation for dehydration and hypotension; fresh frozen plasma (FFP) or fresh whole blood transfusion for DIC and coagulopathy (FFP provides functional clotting factors depleted by DIC-related consumption); 5 percent dextrose supplementation for hypoglycemia from hepatic failure; antiemetics for vomiting; hepatoprotective agents (S-adenosylmethionine (SAMe), silymarin/milk thistle, N-acetylcysteine) to support hepatocyte recovery; avoidance of all hepatotoxic medications (NSAIDs, acetaminophen, tetracyclines, trimethoprim-sulfonamide, azathioprine) during the acute and recovery phases; isolation to prevent nosocomial transmission; vaccination of all in-contact dogs that are currently unvaccinated.
The 14-week-old unvaccinated Labrador Retriever mix had been adopted from a shelter 3 days earlier; the adopters brought him in for his first wellness visit and mentioned he seemed less playful than the day before and had not finished his breakfast that morning; on examination his temperature was 40.8 degrees Celsius, his tonsils were visibly enlarged, the lymph nodes in his neck were palpable, and he winced when the cranial abdomen was palpated; a chemistry panel showed ALT at 9 times the upper reference limit, ALP at 4 times normal, total bilirubin slightly elevated, and albumin low-normal; a complete blood count showed lymphopenia and a platelet count of 88,000 (reference 200,000 to 500,000); abdominal ultrasound demonstrated diffuse hepatomegaly, periportal edema, a small amount of free abdominal fluid, and notably a markedly thickened, edematous gallbladder wall; CAV-1 serology was negative on acute sample; PCR on whole blood returned positive for Canine Adenovirus 1 the following day; the puppy was hospitalized on IV fluids, plasma was administered, and he received intensive supportive care; he survived after 5 days of hospitalization; at the 10-day recheck, the owner noted his eyes had developed a bluish cloudiness on both sides, consistent with the expected post-infectious corneal edema; it resolved over the following 4 weeks without treatment.
The Virus and Why CAV-2 Is in Your Dog’s Vaccine Instead of CAV-1
Vaccine Note: Modern DHPP vaccines contain CAV-2, not CAV-1. CAV-2 provides complete cross-protective immunity against CAV-1 (infectious canine hepatitis) while avoiding the anterior uveitis and “blue eye” that live CAV-1 vaccines caused. CAV-2 also protects against Canine Adenovirus type 2, one component of kennel cough.
| Feature | Canine Adenovirus Type 1 (CAV-1) | Canine Adenovirus Type 2 (CAV-2) |
|---|---|---|
| Disease caused | Infectious canine hepatitis (ICH); severe hepatic necrosis and endothelial injury | Infectious canine tracheobronchitis (one component of kennel cough); respiratory disease |
| Primary target tissues | Hepatocytes, Kupffer cells, vascular endothelial cells throughout the body, corneal endothelium, glomerular endothelium, CNS | Respiratory epithelium of the trachea and bronchi; mild, self-limiting disease in healthy adult dogs |
| Hallmark pathological finding | Cowdry type A intranuclear inclusion bodies in hepatocytes and endothelial cells; DIC; edematous gallbladder wall | Respiratory epithelial degeneration; less severe histopathological changes |
| Vaccine use | Live CAV-1 vaccine: causes effective immunity but also causes post-vaccination anterior uveitis and corneal edema (“blue eye”) in some vaccinated dogs; no longer used in modern vaccines | Live attenuated CAV-2 vaccine: provides complete cross-protection against CAV-1 (shared antigens between CAV-1 and CAV-2 generate cross-reactive neutralizing antibodies) without causing uveitis; used in all current DHPP/DA2PP vaccines |
| Cross-protection | CAV-1 immunity protects against CAV-2 | CAV-2 immunity protects against both CAV-1 and CAV-2 (double benefit from a single vaccine component) |
| Environmental stability | Highly resistant; survives months in contaminated environments; requires bleach or iodine for disinfection | Similar environmental resistance to CAV-1 |
Pathogenesis
Understanding how CAV-1 causes disease helps explain why ICH can be so rapidly fatal and why certain clinical signs appear when they do:
- Entry and initial replication (days 1 to 4): virus enters via oropharyngeal route (oral or nasal contact with infected urine, feces, saliva, or fomites); initial replication in tonsillar crypts and Peyer’s patches of the small intestine; explains the tonsillitis and cervical lymphadenopathy seen in early clinical disease
- Primary viremia (days 4 to 8): virus enters the bloodstream and disseminates throughout the body; lymphopenia occurs during this phase as lymphocytes are destroyed; fever is the systemic response to viremia; this is the window during which clinical signs of acute illness are most prominent
- Hepatic phase (days 5 to 10): CAV-1 infects hepatocytes and Kupffer cells; massive hepatic necrosis with Cowdry type A intranuclear inclusion bodies; ALT, ALP, and bilirubin rise sharply; hepatic failure causes hypoglycemia (loss of glycogen storage and gluconeogenesis) and hypoalbuminemia (loss of albumin synthesis); the characteristic cranial abdominal pain on palpation reflects hepatic swelling and capsule distension
- Endothelial phase and DIC (concurrent with hepatic phase): CAV-1 infects endothelial cells throughout all vascular beds; endothelial necrosis activates the coagulation cascade; platelets are consumed at endothelial injury sites; clotting factors are consumed; DIC develops; clinical signs include thrombocytopenia, petechiae, ecchymoses, prolonged clotting times (PT and aPTT), and bleeding from venipuncture sites; the edematous gallbladder wall results from plasma leakage through damaged gallbladder endothelium
- Renal phase: CAV-1 infects glomerular endothelium; immune complex deposition in the glomerulus causes membranoproliferative glomerulonephritis; glucosuria without hyperglycemia (renal tubular damage) is a characteristic finding; proteinuria; renal failure can contribute to the mortality of severe ICH
- Ocular phase (convalescence, days 7 to 21): immune complex deposition in the corneal endothelium and anterior uvea triggers the inflammatory response responsible for the “blue eye”; this occurs as the immune system mounts an antibody response; the corneal edema is a sign of recovery, not deterioration; in most dogs it resolves without treatment
Clinical Presentation
| Form | Clinical Description | Affected Population | Outcome |
|---|---|---|---|
| Peracute | Dog found dead or dies within hours to 24 hours with no prior signs of illness; no opportunity for clinical intervention; massive hepatic necrosis and DIC cause death before any owner-observable signs develop; sometimes a brief period of severe lethargy or collapse | Very young unvaccinated puppies (4 to 12 weeks), partially immune dogs, dogs with extremely high viral exposure dose | Fatal; no treatment possible |
| Acute (severe) | Fever up to 41.5 degrees Celsius; profound lethargy and anorexia; vomiting; bloody diarrhea; painful cranial abdomen; tonsillitis; cervical lymphadenopathy; petechiae on mucous membranes; prolonged bleeding from venipuncture sites; jaundice in severe cases; seizures if hepatic encephalopathy or CNS involvement | Young unvaccinated dogs 1 to 4 years old; partially vaccinated dogs | Mortality 10 to 30 percent in treated severe cases; survivors often develop post-infectious blue eye during recovery |
| Mild/subacute | Transient fever (1 to 2 days); mild lethargy; reduced appetite; spontaneous recovery without specific treatment; owner may not even seek veterinary care | Most common form; adolescent and adult dogs with partial immunity from vaccination or prior subclinical exposure | Full recovery without treatment |
| Subclinical | No clinical signs; seroconversion detectable on antibody titer; dog becomes immune and sheds virus in urine for months | Vaccinated dogs with partial immunological waning; dogs with prior exposure | No illness; persistent urinary shedding is an infection source for unvaccinated contacts |
Post-Infectious Blue Eye
The blue eye (bilateral or unilateral corneal edema) appearing approximately 7 to 14 days into recovery warrants specific discussion because owners are frequently alarmed by it, especially because it appears as the dog seems to be getting better:
- Mechanism: immune complexes (CAV-1 antigen bound to antibody) deposit in the corneal endothelium and anterior uvea; the inflammatory response to these complexes damages the corneal endothelial pump function, causing corneal stromal edema; the edema produces the characteristic blue-grey opacity
- Timing: typically appears 7 to 10 days after onset of acute illness; the dog is usually clinically improving at the time the blue eye develops
- Resolution: spontaneous resolution in 3 to 4 weeks in most dogs without specific treatment; topical corticosteroid eye drops may be used by some veterinarians to reduce the inflammatory component, though evidence for improved outcomes is limited
- Complications: a minority of dogs (approximately 5 to 10 percent) develop secondary glaucoma or persistent corneal opacity; these cases require ophthalmological evaluation and management
- Vaccine-associated blue eye: identical pathological mechanism; occurs in a small percentage of dogs receiving live CAV-1 vaccines; this is the reason CAV-2 replaced CAV-1 in modern vaccines; the blue eye from CAV-2 vaccination does not occur
Diagnosis
| Test | Finding in ICH | Notes |
|---|---|---|
| CBC | Lymphopenia (early viremia phase); neutrophilia (inflammation); thrombocytopenia (DIC, platelet consumption); anemia (blood loss in severe hemorrhagic disease) | Lymphopenia is an early finding; thrombocytopenia indicates DIC and worsening prognosis; platelet counts below 50,000 indicate severe coagulopathy |
| Chemistry panel | Markedly elevated ALT and ALP (hepatocellular necrosis); elevated total bilirubin; decreased albumin; hypoglycemia (hepatic failure); elevated BUN and creatinine if renal involvement | ALT elevation is often dramatic (5 to 20 times upper reference limit); glucosuria without hyperglycemia on urinalysis (renal tubular damage) is characteristic |
| Coagulation panel (PT, aPTT) | Prolonged PT and aPTT (DIC consuming clotting factors); elevated fibrin degradation products (FDPs); hypofibrinogenemia | Coagulation testing should be performed before any invasive procedures; prolonged clotting times indicate DIC and risk of life-threatening hemorrhage from venipuncture or surgery |
| Abdominal ultrasound | Hepatomegaly; increased hepatic echogenicity or mixed echotexture; periportal edema (hyperechoic halo around portal vessels); free peritoneal fluid (serosanguineous); edematous gallbladder wall (pathognomonic finding) | Gallbladder wall edema greater than 3 mm is characteristic of ICH; this finding on ultrasound in an unvaccinated young dog with acute hepatopathy strongly supports ICH diagnosis |
| PCR (whole blood) | CAV-1 DNA detected during viremic phase (days 4 to 8 of illness); highly sensitive and specific; differentiates CAV-1 from CAV-2 | Preferred confirmatory test in living dogs; results typically available within 24 to 48 hours from reference lab; PCR can be negative after viremia resolves even when clinical signs persist |
| Serology (paired titers) | Fourfold or greater rise in CAV-1 neutralizing antibody titer between acute (day 0 to 5) and convalescent (day 14 to 21) samples confirms recent infection; a single high titer is difficult to interpret without vaccination history | Useful for retrospective confirmation; vaccinated dogs may have baseline titers from CAV-2 vaccine that complicate interpretation; IgM-specific serology can support acute infection |
| Post-mortem histopathology | Cowdry type A intranuclear inclusion bodies in hepatocytes, Kupffer cells, and vascular endothelial cells; centrilobular to massive hepatic necrosis; edematous gallbladder wall; hemorrhages throughout organs; glomerulonephritis | Gold standard for definitive diagnosis; intranuclear inclusion bodies confirmed by immunohistochemistry with CAV-1-specific antibodies |
Treatment
| Intervention | Indication and Approach |
|---|---|
| IV crystalloid fluid therapy | Lactated Ringer’s or Plasmalyte for dehydration, hypovolemia, and hypotension; fluid rate based on degree of dehydration and ongoing losses; avoid excess fluids in cases with severe hypoalbuminemia and ascites to prevent further edema formation; colloids (hydroxyethyl starch, albumin) may be needed to maintain oncotic pressure when albumin is critically low |
| Fresh frozen plasma (FFP) | Provides functional clotting factors (II, V, VII, VIII, IX, X, XI, fibrinogen) depleted by DIC; indicated when PT or aPTT is prolonged greater than 1.5 times normal, when platelet count is below 50,000 with active bleeding, or when active hemorrhage is observed; dose: 10 to 20 mL/kg IV slowly; may require multiple doses; most impactful intervention for managing DIC in ICH |
| Dextrose supplementation | 2.5 to 5 percent dextrose added to IV fluids for hypoglycemia from hepatic failure; monitor blood glucose every 2 to 4 hours and adjust supplementation; hypoglycemia contributes to the CNS signs (seizures, disorientation) in hepatic failure |
| Antiemetics | Maropitant (Cerenia) 1 mg/kg SQ once daily; ondansetron 0.1 to 0.15 mg/kg IV or orally for refractory vomiting; important because vomiting worsens dehydration and prevents oral medication administration |
| Hepatoprotective agents | SAMe (S-adenosylmethionine): 18 to 20 mg/kg orally once daily (on empty stomach); replenishes hepatic glutathione; N-acetylcysteine: 70 mg/kg IV loading dose then 35 mg/kg IV every 6 hours; direct antioxidant for hepatocyte oxidative injury; silymarin (milk thistle): 50 to 100 mg orally twice daily; evidence for efficacy is limited but these agents are low-risk and widely used as adjuncts |
| Whole blood transfusion | For severe anemia (PCV below 20 percent) secondary to hemorrhage; fresh whole blood provides both red cells and clotting factors; preferred over packed red cells in DIC because it provides coagulation factors as well |
| Nutritional support | Early enteral nutrition (nasogastric tube if vomiting is controlled) supports hepatic regeneration and reduces bacterial translocation; hepatic failure dogs should receive a digestible, moderate-protein diet; do not restrict protein excessively unless hepatic encephalopathy is present |
| Drugs to AVOID | NSAIDs (meloxicam, carprofen, deracoxib): hepatotoxic, reduce renal blood flow, and promote GI hemorrhage; tetracyclines: hepatotoxic; trimethoprim-sulfonamide: hepatotoxic, risk of coagulopathy; azathioprine: hepatotoxic; acetaminophen: toxic in dogs at any dose; all hepatotoxic drugs until liver values normalize; do not use heparin for DIC in dogs without specialist guidance, as heparin carries risk of worsening hemorrhage |
Environmental Decontamination and Isolation
CAV-1’s environmental persistence makes decontamination essential after any confirmed case:
- Effective disinfectants: sodium hypochlorite bleach (household bleach) at 1:30 dilution (approximately 1 cup bleach per 2 gallons water) with a minimum 10-minute contact time; iodine-based disinfectants (povidone-iodine diluted to working concentration); formaldehyde (impractical for most facilities); steam cleaning above 55 degrees Celsius
- Ineffective disinfectants: quaternary ammonium compounds (QACs) such as benzalkonium chloride, which are commonly used in kennels but do NOT kill non-enveloped viruses including CAV-1, canine parvovirus, or feline calicivirus; chlorhexidine alone; alcohols in standard concentrations
- Isolation of affected and recovered dogs: dogs with active ICH should be strictly isolated from unvaccinated dogs for the duration of illness and for at least 6 months after recovery due to persistent urinary shedding; recovered dogs should not share outdoor spaces, water bowls, or bedding with unvaccinated dogs during the shedding period
- Urine decontamination: all surfaces and areas where the infected or recovered dog has urinated should be thoroughly cleaned and disinfected with bleach solution; porous surfaces (soil, grass, unsealed concrete) are difficult to decontaminate completely and may harbor virus for extended periods
- Vaccination of in-contact dogs: all unvaccinated dogs exposed to a confirmed ICH case should receive emergency vaccination immediately; vaccination after exposure may reduce severity of disease if given before clinical signs develop
Age-Specific Considerations
Puppies (Under 6 Months)
- Puppies under 4 to 6 months are the highest-risk group for severe and peracute ICH because they have not yet completed their primary vaccination series and because maternal antibody levels decline sharply between 6 and 16 weeks, creating a window of vulnerability; a puppy that received adequate maternal antibody from a vaccinated dam may be temporarily protected but becomes susceptible as maternal antibodies wane; the maternal antibody window of vulnerability for ICH overlaps with the window for parvovirus and distemper, which is why completing the full puppy vaccination series on schedule (at 6 to 8, 10 to 12, and 14 to 16 weeks) is so important; a single missed or delayed vaccination appointment can leave a puppy unprotected during the period of highest exposure risk from socialization, puppy classes, or shelter environments
- The peracute presentation of ICH, in which a puppy is found dead or dies within hours without any prior illness, occurs almost exclusively in this age group; owners who have recently adopted or purchased an unvaccinated or incompletely vaccinated puppy that dies suddenly without prior signs should request a post-mortem examination; ICH is one of the diagnoses that explains sudden death in apparently healthy young dogs alongside hypoglycemia, congenital cardiac defects, and canine herpesvirus neonatal disease; the post-mortem finding of intranuclear inclusion bodies in the liver and a grossly edematous gallbladder wall confirms ICH
- Puppies surviving acute ICH are expected to develop the post-infectious blue eye in approximately 20 to 25 percent of cases at the 1 to 2-week mark after peak illness; owners should be counseled to expect this possibility and instructed to return for ocular re-evaluation if corneal cloudiness appears; the concurrent presence of corneal edema in a puppy recovering from an acute hepatic illness in the right time frame is practically diagnostic of ICH without additional testing
Adult Dogs (1 to 8 Years)
- Vaccinated adult dogs with current DHPP vaccination have excellent protection against CAV-1 and clinical ICH is rare in this population in developed countries with high vaccination compliance; vaccine-induced CAV-2 immunity produces neutralizing antibodies against both CAV-1 and CAV-2 that persist for 3 or more years after vaccination in most dogs; the duration of immunity for the CAV component of DHPP has been studied and found to be 3 years or longer in most dogs after appropriate primary vaccination, supporting the triennial adult booster recommendations of many veterinary organizations; adult dogs in regions with poor vaccination compliance (some international areas, some rural regions of the United States) face real ongoing exposure risk from wildlife reservoir hosts, particularly red foxes
- Adult dogs that were poorly vaccinated as puppies (e.g., received only 1 or 2 doses with poor timing, or were vaccinated with compromised vaccine product) may have inadequate CAV-1 immunity despite owner belief that they are vaccinated; titer testing (CAV-1 neutralizing antibody titer) is available at reference laboratories and can be used to assess immune status in an adult dog of uncertain vaccination history before international travel, boarding in high-risk facilities, or other situations where exposure risk is elevated; a protective titer suggests adequate immunity; a low or undetectable titer warrants revaccination
- Dogs working or living in environments with fox contact (hunting dogs, rural dogs, wildlife rehabilitation workers’ dogs) face ongoing CAV-1 exposure risk from infected red foxes; fox populations in many regions of the US, UK, and Europe maintain endemic CAV-1 infection; these dogs benefit from current vaccination status with DHPP maintained rigorously, which is especially important because wildlife exposure events are unpredictable; foxes shed CAV-1 in urine, feces, and secretions and infected foxes may enter yards, farms, or areas frequented by dogs
Senior Dogs (9 Years and Older)
- Senior dogs with current vaccination have the same excellent protection against clinical ICH as vaccinated adult dogs; the primary concern in senior dogs with respect to CAV-1 is the durability of vaccine immunity in an aging immune system; studies examining vaccine antibody titer persistence in geriatric dogs suggest that most dogs maintain protective titers for 3 years after booster vaccination, but a subset of elderly dogs may have lower titers than expected due to immunosenescence; for senior dogs that board frequently, travel internationally, or live in areas with endemic wildlife CAV-1, titer testing before a planned high-risk exposure period and revaccination if titers are low is a reasonable approach, though it is not universally practiced
- Senior dogs presenting with acute hepatopathy (elevated liver enzymes, hepatomegaly, abdominal pain) in a context of uncertain vaccination history should have ICH on the differential diagnosis alongside other causes of acute hepatitis including leptospirosis (see the leptospirosis post), toxic hepatopathy from mushroom or xylitol ingestion, hepatic neoplasia, and cholangiohepatitis; the combination of abdominal ultrasound showing gallbladder wall edema plus a young or unvaccinated dog would strongly support ICH, but senior dogs with unknown vaccination histories can also be affected; CAV-1 PCR and serology can confirm the diagnosis in a senior dog with acute hepatopathy of unclear etiology
- Senior dogs with chronic hepatic disease (fibrosis, cirrhosis, portosystemic shunting) from prior CAV-1 infection represent a rarely discussed consequence of ICH; dogs that survive severe acute ICH may develop chronic hepatic fibrosis as a sequela of extensive hepatocellular necrosis; these dogs present months to years later with chronic liver disease signs (weight loss, ascites, hepatic encephalopathy, coagulopathy) unrelated to any current infectious exposure; the prior ICH history may be documented or may be entirely unknown (the dog survived a subclinical or mild infection years earlier); chronic hepatic fibrosis post-ICH is managed with the same supportive measures used for other causes of chronic liver disease
Myths and Facts About Infectious Canine Hepatitis
Myth
My dog was vaccinated, so the vaccine already gave it hepatitis and I do not need to worry about it getting ICH from other dogs.
Fact
Modern DHPP vaccines contain CAV-2 (not CAV-1), which does not cause hepatitis; CAV-2 produces respiratory disease in a mild form but does not infect hepatocytes. The vaccine trains the immune system to produce neutralizing antibodies that cross-protect against CAV-1. A vaccinated dog with a current, properly administered DHPP series has excellent protection against ICH and will not develop hepatitis from CAV-1 exposure unless the immune response has waned significantly. The vaccine does not cause hepatitis.
Myth
My dog’s eyes turned blue while recovering from a liver illness, which means the liver disease is spreading to the eyes and the prognosis is getting worse.
Fact
The blue eye (corneal edema) appearing during recovery from ICH is a sign of immune response, not worsening disease. It develops 7 to 14 days into convalescence when the dog’s immune system mounts an antibody response against the virus; immune complexes deposit in the corneal endothelium and trigger temporary edema. In most dogs it resolves in 3 to 6 weeks without treatment. Seeing the blue eye in a recovering dog means the immune system is responding, not that the disease is progressing.
Myth
My dog recovered from ICH last month and is back to normal, so I can bring it to the dog park and introduce it to my neighbor’s unvaccinated dog now.
Fact
Dogs recovering from ICH shed CAV-1 in their urine for up to 6 to 9 months after clinical recovery. A dog that looks and feels completely healthy can still shed infectious virus in its urine for the better part of a year. Contact with unvaccinated dogs during this period puts those dogs at risk. A recovered dog should be kept away from unvaccinated dogs and shared spaces for at least 6 months post-recovery. All in-contact unvaccinated dogs should be vaccinated immediately.
Red Flags: Signs Requiring Emergency Veterinary Evaluation
- Any unvaccinated or incompletely vaccinated puppy or young dog with sudden severe lethargy, high fever, vomiting, and abdominal pain concentrated in the cranial abdomen (front half of the belly): this combination in an unvaccinated dog is a potential ICH emergency; simultaneously, parvovirus and leptospirosis must be ruled out because all three present with acute collapse-level illness in young unvaccinated dogs; do not wait to see if the dog “sleeps it off”
- Visible petechiae (pinpoint red hemorrhages) on gums or skin, ecchymoses (bruising), bleeding from venipuncture sites that does not stop normally, or blood in vomit, urine, or stool in a young sick dog: these are signs of DIC and indicate a life-threatening coagulopathy that can kill within hours; emergency hospitalization with plasma transfusion is the only effective intervention
- Sudden collapse or death of a young unvaccinated dog with no prior illness: peracute ICH can kill within hours of first signs (or before any signs are visible to the owner); a post-mortem examination should be requested for any sudden unexplained death in an unvaccinated young dog to identify the cause and protect other dogs in the household or kennel
- Seizures or disorientation in a dog with concurrent elevated liver enzymes: hepatic encephalopathy from acute liver failure in ICH presents with CNS signs that require emergency treatment (IV dextrose, lactulose, dietary protein modification, treatment of the underlying hepatic failure)
- Corneal cloudiness (blue or grey opacity) in either or both eyes of a dog that recently recovered from acute liver disease and fever: post-infectious blue eye requires ophthalmological evaluation to differentiate straightforward convalescent corneal edema (expected to resolve) from early secondary glaucoma (requires active treatment to prevent permanent vision loss); do not assume all blue eye resolves without complications
US Cost Overview for Infectious Canine Hepatitis
| Service | Typical US Cost |
|---|---|
| Veterinary examination | $60 to $150 |
| CBC and chemistry panel | $80 to $160 |
| Coagulation profile (PT, aPTT, FDPs) | $60 to $120 |
| Abdominal ultrasound | $200 to $500 |
| CAV-1 PCR (reference lab) | $60 to $120 |
| Hospitalization per day (IV fluids, monitoring) | $400 to $900 |
| Fresh frozen plasma transfusion | $150 to $400 per unit |
| DHPP vaccine (preventive) | $20 to $50 |
| Total for mild outpatient case | $300 to $700 |
| Total for severe hospitalized case (3 to 5 days) | $2,000 to $6,000 |
Frequently Asked Questions About Infectious Canine Hepatitis
What is infectious canine hepatitis?
Infectious canine hepatitis (ICH) is a potentially fatal liver and vascular disease caused by Canine Adenovirus type 1 (CAV-1). The virus attacks hepatocytes (liver cells) and vascular endothelial cells throughout the body. Severe cases cause massive liver necrosis, disseminated intravascular coagulation (DIC), and death. It primarily affects unvaccinated or incompletely vaccinated puppies and young dogs. The DHPP vaccine (containing CAV-2) provides complete cross-protective immunity.
What does CAV-1 do to a dog’s liver?
CAV-1 infects hepatocytes and Kupffer cells, causing necrosis from centrilobular to massive, depending on severity. The virus produces characteristic Cowdry type A intranuclear inclusion bodies visible on histopathology. Liver enzyme elevation (ALT and ALP) is dramatic. Simultaneously, the virus infects vascular endothelial cells throughout the body, causing disseminated intravascular coagulation. At necropsy, the grossly edematous gallbladder wall and intranuclear inclusions in liver and endothelial cells confirm the diagnosis.
What is the “blue eye” associated with hepatitis in dogs?
The blue eye (corneal edema) appears in approximately 20 to 25 percent of dogs during convalescence, typically 7 to 14 days after the acute illness. Immune complexes deposit in the corneal endothelium and trigger inflammation that disrupts the corneal endothelial pump, causing stromal edema and a blue-grey corneal opacity. It is a sign of immune response, not worsening disease. Most cases resolve in 3 to 6 weeks without treatment. A small percentage develop secondary glaucoma requiring active management.
How is infectious canine hepatitis treated?
Treatment is supportive: IV fluids for dehydration and hypotension; fresh frozen plasma (FFP) for DIC and coagulopathy (FFP provides clotting factors depleted by DIC); dextrose supplementation for hypoglycemia from liver failure; antiemetics; hepatoprotective agents (SAMe, N-acetylcysteine); avoidance of all hepatotoxic medications. No specific antiviral therapy exists. Severity varies from mild (self-resolving) to severe (potentially fatal even with treatment).
How long does a recovered dog shed the CAV-1 virus?
Dogs recovering from ICH shed CAV-1 in their urine for up to 6 to 9 months after clinical recovery. The dog appears completely healthy but remains infectious to unvaccinated dogs through urinary contact. Recovered dogs should be kept away from unvaccinated dogs and shared spaces for at least 6 months post-recovery. All in-contact unvaccinated dogs should be vaccinated immediately.
Is infectious canine hepatitis in dogs contagious to humans?
No. Canine Adenovirus type 1 is specific to dogs and wild canids (foxes, wolves, coyotes, bears). It does not infect humans or other domestic species. ICH poses no zoonotic risk to people living with affected dogs. Human adenoviruses are distinct from CAV-1 and cause respiratory illness in humans; they are not related to CAV-1.
Does the DHPP vaccine protect against infectious canine hepatitis?
Yes, with excellent efficacy. Modern DHPP (also labeled DA2PP) vaccines contain live attenuated CAV-2, which generates neutralizing antibodies that cross-protect against both CAV-1 (hepatitis) and CAV-2 (respiratory). Duration of immunity is 3 or more years in most vaccinated dogs. Completing the full puppy series and maintaining adult boosters per veterinary recommendations provides reliable protection against ICH throughout a dog’s life.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles